Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
CONCLUSIONS: On-market generic drug products continue to be reference-bioequivalent and are bioequivalent to each other based on AUCT, AUCI, and Cmax but not AUCReftmax. Average deviation of geometric mean ratios and intra-subject variations are similar between reference-generic and generic-generic comparisons.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01344070 (registered April 3, 2011).
PMID: 29216899 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Amoxicillin | Atenolol | Biaxin | Cephalexin | Cipro | Ciprofloxacin | Clarithromycin | Diclofenac | Drugs & Pharmacology | Fluconazole | Fortamet | Ibuprofen | Metformin | Metronidazole | Middle East Health | Norvasc | Omeprazole | Prilosec | Ranitidine | Saudi Arabia Health | Study | Toxicology | Voltaren